en · de · es · fr · pt
bpc-157-notes.peptides9000.com › Data › Bpc-157 Identity And Origin — Complete Guide

Bpc-157 Identity And Origin — Complete Guide

By Editorial Desk · published 2026-04-28 · last reviewed 2026-06-04 · Data

A practical reference on amino acid sequence: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.

Reviewed 2026-06-04. Anything still debated is marked as such rather than presented as settled.

BPC-157 Identity and Origin

BPC-157 is a synthetic peptide of fifteen amino acids, written in single-letter code as GEPPPGKPADDAGLV. The sequence corresponds to a partial fragment of a protein isolated from human gastric juice, described in early reports as body protection compound. The number 157 refers to a fragment designation in that work rather than to molecular mass. Initial descriptions appeared in the early 1990s, when the fragment was reported to protect gastrointestinal tissue in animal models. Commercial material is produced by solid-phase peptide synthesis rather than extracted from biological sources.

Laboratory research on this peptide has examined a wide and heterogeneous set of endpoints, including gastric ulcer models, tendon and ligament injury, wound closure, and intestinal inflammation. Most published findings come from rodent studies, and reported effect sizes are often large relative to controls. Because the compound has been tested across many unrelated injury models, the literature is frequently described as unusually broad for a single peptide. A substantial share of this work originates from a small number of research groups, which matters when assessing how widely results have been reproduced.

Evidence in humans is limited. Small clinical studies have examined the peptide in contexts such as ulcerative colitis and wound healing, but participant numbers are small and independent replication is scarce. It is not approved as a medicine by major regulatory agencies and is distributed mainly as a research material or compounded preparation. Long-term human safety data are not established, and questions about absorption through non-injected routes remain open rather than resolved. Claims about its effects are best read against these gaps.

Background and Chemical Identity

The molecule carries 15 residues, a molar mass near 1419.5 g/mol, and the formula C62H98N16O22. Its structure features a proline-rich central region, a pair of adjacent aspartic acid residues, and no cysteine. The absence of cysteine means no disulfide bonds can form, which simplifies refolding and reconstitution. Suppliers usually ship the material as a freeze-dried powder that appears white to off-white. It dissolves readily in water and in saline solutions.

Published storage guidance follows general peptide practice rather than product-specific studies. The dry powder is typically kept at minus 20 degrees Celsius, away from light and moisture. Once reconstituted, solutions are generally refrigerated and used over days to weeks, because the aqueous environment slowly promotes hydrolysis and oxidation. Long-term data on degradation rates or breakdown products are sparse. Stated shelf lives from different producers vary widely, reflecting the absence of a shared reference standard.

BPC-157 is a synthetic peptide built from fifteen amino acid residues. Its sequence comes from a larger protein fragment that researchers isolated from human gastric juice and described as a body protection compound. The fragment contains glycine, glutamic acid, five prolines, lysine, alanine, two aspartic acids, leucine, and valine. The number 157 in the name refers to the position of the stretch within the parent protein. Material used in laboratories is manufactured rather than extracted from stomach fluid.

Bpc-157 at a glance

PropertyValueNotes
ClassSynthetic peptideLinear, fifteen residues
SequenceGEPPPGKPADDAGLVSingle-letter amino acid code
Approximate mass1419 DaValue reported for the free peptide
Reported originFragment of a gastric juice proteinUsed as the design template
Common synonymsBody protection compound 157; PL 14736Naming varies across papers and suppliers

Origin and Peptide Identity

BPC-157 is a synthetic pentadecapeptide whose sequence is commonly given as Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is described in the literature as a fragment of a larger protein found in human gastric juice, referred to as body protection compound. The peptide was first characterized in the early 1990s by a research group in Zagreb, Croatia. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.

Supplied material is typically a lyophilized white to off-white powder. The peptide is freely soluble in water and in common aqueous buffers, which allows it to be handled as a stock solution. Because the sequence contains no cysteine, disulfide cross-linking is not a route of degradation. The absence of aromatic residues means ultraviolet absorbance at 280 nm is minimal, so quantification usually relies on peptide bond absorbance near 214 nm or on amino acid analysis.

Common synonyms in catalogs include pentadecapeptide BPC 157, BPC157, and the full sequence name. A CAS registry number in the 137525-51-0 range is frequently listed, though the assignment should be verified against the supplier certificate of analysis. The name itself is not a pharmacopoeial designation, and there is no standardized international nonproprietary name. Distinguishing genuine material from related fragments generally requires mass spectrometry, since several truncated sequences share similar chromatographic behavior.

Related pages on this site

Identity And Chemical Background

The sequence places several glycine and proline residues near the middle, which may influence how the chain folds in solution. The peptide is linear rather than cyclic, and it carries no disulfide bridges. Commercial material is commonly supplied as the acetate salt, although the free base and other counterion forms also appear. Because the term BPC-157 refers to a specific sequence, samples with slight sequence variants are chemically different substances. Published work generally treats the fifteen-residue sequence as the defining structure.

Physical descriptions in supplier documents and papers usually list the compound as a white to off-white powder. It dissolves readily in water and in common aqueous buffers, and solutions are often prepared fresh before an experiment. Molecular mass near 1419 daltons helps verify identity during mass spectrometry. The powder is somewhat hygroscopic, so moisture exposure can alter the measured mass of a sample. Purity is typically reported as a percentage from chromatographic analysis.

BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence is GEPPPGKPADDAGLV. Its name derives from the phrase body protection compound, a term applied to a protein fraction originally detected in human gastric juice. The short peptide is not that full protein; it corresponds to a stable fragment of the larger molecule. Researchers frequently describe it as a pentadecapeptide because it contains exactly fifteen residues. Its neutral molecular mass is approximately 1419 daltons.

Background from the literature

=== India === Specialty training in India is overseen by the National Medical Commission (formerly Medical Council of India), responsible for recognition of post graduate training and by the National Board of Examinations. Education of Ayurveda in overseen by Central Council of Indian Medicine (CCIM), the council conducts UG and PG courses all over India, while Central Council of Homoeopathy does the same in the field of Homeopathy. Specialization and superspecialization in medicine and surgery are pursued after completing MBBS, for which higher medical (MD, DM) and surgical (MS, MCh) degrees are awarded. The following medical and surgical specialties and superspecialties are recognized by the National Medical Commission (formerly Medical Council of India) and National Board of Examinations in Medical Sciences:

The Gβγ sub-unit binds to the intracellular loop between the two trans-membrane helices of the VDCC. When the sub-unit binds to the voltage-dependent calcium channel, it produces a voltage-dependent block, which inhibits the channel, preventing the flow of calcium ions into the neuron. Embedded in the cell membrane is also the G protein-coupled inwardly-rectifying potassium channel. When a Gβγ or Gα(GTP) molecule binds to the C-terminus of the potassium channel, it becomes active, and potassium ions are pumped out of the neuron. The activation of the potassium channel and subsequent deactivation of the calcium channel causes membrane hyperpolarization. This is when there is a change in the membrane's potential, so that it becomes more negative. The reduction in calcium ions causes a reduction of neurotransmitter release because calcium is essential for this event to occur. This means that neurotransmitters such as glutamate and substance P cannot be released from the presynaptic terminal of the neurons. Substance P is a believed to help sensitize postsynaptic neurons to glutamate, aiding in the transmission of pain signals from periphery nerves to the brain. These neurotransmitters are vital in the transmission of pain, and as β-Endorphin reduces the release of these substances, there is a strong analgesic effect.

this aspect is generally overlooked when evaluating DDIs in drug development." Aarons had collaborated on earlier research published in 2008 used physiologically based pharmacokinetic modelling (PBPK) to "evaluate the potential CYP3A4 inhibitory effect of a drug in development." There had been a paper that described the methodology of the trial, and the second paper analysed the results, which showed that although the drug-drug interaction was slightly less than predicted, valuable assessment of the interaction was achieved and could be applied in drug development.

=== Harm and litigation === A similar drug, aminorex, had caused severe lung damage and "provided reason to worry that similar drugs ... could increase the risk of a rare but often fatal lung disease, pulmonary hypertension." In 1994, Wyeth official Fred Wilson expressed concerns about fenfluramine's labeling containing only four cases of pulmonary hypertension when a total of 41 had been observed, but no action was taken until 1996. In 1995, Wyeth introduced dexfenfluramine (the dextro isomer, marketed as Redux), which it hoped would cause fewer adverse effects. However, the medical officer of the Food and Drug Administration (FDA), Leo Lutwak, insisted upon a black box warning of pulmonary hypertension risks. After Lutwak refused to approve the drug, the FDA management had James Milton Bilstad, FDA Senior Drug Evaluator, sign it and approve the drug with no black box warning for marketing in 1996. European regulators required a major warning of pulmonary hypertension risks. In 1996, a 30-year-old woman developed heart problems after a month of using fenfluramine/phentermine; when she died in February 1997, the Boston Herald devoted a front-page article to her. In August 1997, a paper in the New England Journal of Medicine (NEJM) from the Mayo Clinic discussed clinical findings in 24 people who had taken fen-phen. The authors noted that their findings suggested a possible correlation between mitral valve dysfunction and the use of these anorectic agents.

Sources: en.wikipedia.org

Further detail

==== Androgenic ==== Androgen replacement therapy for men with low levels of testosterone, such as those associated with late-onset hypogonadism; also effective in improving libido for elderly males. Induction of male puberty: Androgens are given to many boys distressed about extreme delay of puberty. Testosterone is now nearly the only androgen used for this purpose and has been shown to increase height, weight, and fat-free mass in boys with delayed puberty. Masculinizing hormone therapy for transgender men, other transmasculine people, and intersex people, by producing masculine secondary sexual characteristics such as a deeper voice, increased bone and muscle mass, masculine fat distribution, facial and body hair, and clitoral enlargement, as well as mental changes such as alleviation of gender dysphoria and increased sex drive.

==== Proteases ==== Originally thought to only disrupt enzymatic reactions, proteases (also known as peptidases) actually help with catabolizing proteins through cleavage and creating new proteins that were not present before. Proteases also help to regulate metabolic pathways. One way they do this is to cleave enzymes in pathways that do not need to be running (i.e. gluconeogenesis when blood glucose concentrations are high). This helps to conserve as much energy as possible and to avoid futile cycles. Futile cycles occur when the catabolic and anabolic pathways are both in effect at the same time and rate for the same reaction. Since the intermediates being created are consumed, the body makes no net gain. Energy is lost through futile cycles. Proteases prevent this cycle from occurring by altering the rate of one of the pathways, or by cleaving a key enzyme, they can stop one of the pathways. Proteases are also nonspecific when binding to substrate, allowing for great amounts of diversity inside the cells and other proteins, as they can be cleaved much easier in an energy efficient manner.

==== Potassium ==== A sodium load augments the intense potassium excretion by cortisol. Corticosterone is comparable to cortisol in this case. For potassium to move out of the cell, cortisol moves an equal number of sodium ions into the cell. This should make pH regulation much easier (unlike the normal potassium-deficiency situation, in which two sodium ions move in for each three potassium ions that move out—closer to the deoxycorticosterone effect).

Sources: en.wikipedia.org

Background from the literature

The violent anti-Peruvian demonstrations in Ecuador and anti-Ecuadorian demonstrations in Peru, the mobilization of forces in both countries, everything made us hope that the armed conflict would break out in 1910, had it not been for the intervention of the United States, Brazil and Argentina. The hostilities between the two do not cease, which leads Ecuador in 1910 to establish a defensive alliance with Colombia, giving it 180,000 km2 of the Amazon area for payment, in exchange for strengthening a possible anti-Peruvian alliance between the two. A gesture that Colombia would betray in the eyes of Ecuador by ceding in 1922 to Peru, the common enemy, half of the territories ceded by it. In the middle of the 20th century, the degree of hostility would have increased to the point of a first armed confrontation in 1941, prompted by a seizure of Peruvian Amazonian territories at the hands of the Ecuadorian army, particularly the rubber zone. During the 2nd Peruvian-Ecuadorian War, the Porotillo Massacre broke out, whereby the Peruvian platoon, commanded by Alfredo Novoa Cava, was massacred in Cune by Ecuadorian troops on September 11, 1941, leaving only one survivor (the captain's nephew); This event, carried out in full truce, filled the Ecuadorian chiefs and officers with pride due to strong anti-Peruvian feelings, but not all the soldiers that made up the Ecuadorian detachment, who felt terrified by the fact that their superiors celebrated as one " victoria" a crime against humanity.

== Treatment == The treatment aims to create an environment that allows skin to grow across an ulcer. In most cases, this requires finding and treating underlying venous reflux. The National Institute for Health and Care Excellence (NICE) recommends referral to a vascular service for anyone with a leg ulcer that has not healed within two weeks or anyone with a healed leg ulcer. Most venous ulcers respond to patient education, elevation of the foot, elastic compression, and evaluation (known as the Bisgaard regimen). Exercise together with compression stocking increases healing. There is no evidence that antibiotics, whether administered intravenously or by mouth, are useful. Silver products are also not typically useful, while there is some evidence of benefit from cadexomer iodine creams. There is a lack of quality evidence regarding the use of medical-grade honey for venous leg ulcers. The recommendations for dressings to treat venous ulcers vary between the countries. Antibiotics are often recommended to be used only if advised by the physician due to the emergence of bacterial resistance to antibiotics. This is an issue with venous ulcers as they tend to heal more slowly than acute wounds, for example. Natural alternatives that are suitable for long-term use exist on the market, such as honey and resin salve. These products are considered as Medical Devices in EU and the products have to be CE marked. Sugar has long been known for its effectiveness in wound treatment, notably through the use of honey or powdered sugar.

=== Disassociation === Ensuring that every specimen has an individual accession number will reduce the risk of disassociation. The accession number relates that number to an identifiable object and the object can only be moved if its location is updated, ensuring the object is never disassociated from its data. Most herbaria utilize a standard system of organizing their specimens into herbarium cases. Specimen sheets are stacked in groups by the species to which they belong and placed into a large lightweight folder that is labeled on the bottom edge. Groups of species folders are then placed together into larger folders by genus. The genus folders are then sorted by taxonomic family according to the standard system selected for use by the herbarium and placed into pigeonholes in herbarium cabinets. Locating a specimen filed in the herbarium requires knowing the nomenclature and classification used by the herbarium. It also requires familiarity with possible name changes that have occurred since the specimen was collected, since the specimen may be filed under an older name. Modern herbaria often maintain electronic databases of their collections. Many herbaria have initiatives to digitize specimens to produce a virtual herbarium. These records and images are made publicly accessible via the Internet when possible.

In the points where the image is present, the discoloration affects only two or three fibers on the topmost part of the threads of the cloth. In each fiber, the yellow discoloration penetrates only for 200 nm in the external cell layer. A fiber is not necessarily colored for all its length, but, in the parts where it is, it has the property of being colored all around its cylindrical surface. Under the crossing threads of the weave, the image is not present. The discoloration seems caused by a kind of dehydrative oxidation process, which has discolored and chemically altered the surfaces of certain surface fibrils. The image of the Shroud is an areal density image, in the sense that the levels of darkness are not given by variations of the color, which instead is approximately constant all over the image, but by a variation of the number of yellowed fibers per unit area. Therefore, it can be considered a halftone image. Furthermore, there is no difference in terms of distribution of fiber coloration and maximum densities between the front and the rear of the image. While the blood images could have come from a contact mechanism, the body image could not. The mapping between body-only image densities and expected cloth–body distances is not consistent with the image having been formed by direct contact with a body, as it is present even when it does not seem possible for the cloth to be in contact with the body.

Sources: en.wikipedia.org

Frequently asked questions

What is BPC-157 chemically?

It is a synthetic fifteen-amino-acid peptide whose sequence matches part of a protein found in human gastric juice. It is made by chemical synthesis, not purified from tissue. The name derives from an early fragment label, not from a molecular weight.

Does it occur naturally in the body?

The sequence corresponds to a segment of a naturally occurring gastric protein, so related sequence material exists in the body. The peptide itself as sold and studied is a laboratory-synthesized product. Whether an identical free peptide circulates naturally is not established.

Is it an approved drug?

No major regulatory agency has approved it as a medicine for any indication. It appears in research supply channels and, in some jurisdictions, in compounded preparations. Clinical use therefore sits outside standard approved-product pathways, and regulatory status varies by country.

Is BPC-157 a naturally occurring peptide?

It does not occur in the form that is supplied commercially. Its sequence matches a fragment of a larger gastric protein, and the research material is produced synthetically in a laboratory. The fragment described in the early literature is generally the same synthetic pentadecapeptide.

Network